Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
Clin Biochem ; 125: 110719, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38316335

ABSTRACT

BACKGROUND: Increased cerebrospinal fluid (CSF) ß2-microglobulin (ß2-MG) values are attributed to immune activation, lymphoid cell turnover and release of tissue destruction in the central nervous system (CNS). We investigated plasma and CSF ß2-MG levels in adult patients with viral encephalitis/meningitis and their correlations with clinical parameters. METHOD: CSF samples from 26 patients with viral encephalitis/meningitis were collected. Moreover, 24 CSF samples from patients with non-inflammatory neurological disorders (NIND) as controls were collected. Plasma samples from 22 enrolled patients and 20 healthy individuals were collected. The ß2-MG levels were measured by immunoturbidimetry on an automatic biochemical analyzer. Clinical data were extracted from an electronic patient documentation system. RESULT: CSF levels of ß2-MG, adenosine deaminase (ADA), white blood cell (WBC), lactate dehydrogenase (LDH), protein and lactate were significantly increased in patients with viral encephalitis/meningitis respectively (p < 0.001, p < 0.001, p < 0.001, p = 0.001, p < 0.001, p = 0.013). In contrast, no statistically significant difference was found in plasma levels of ß2-MG. Furthermore, CSF levels of ß2-MG were weakly correlated with WBC (r = 0.426, p = 0.030), lymphocyte percentage (r = 0.599, p = 0.018), ADA (r = 0.545, p = 0.004) and LDH (r = 0.414, p = 0.036), but not with lactate (r = 0.381, p = 0.055), protein (r = 0.179, p = 0.381) and plasma levels of ß2-MG (r = -0.156, p = 0.537) in viral encephalitis/meningitis patients. CONCLUSION: CSF ß2-MG may be a potential inflammatory marker for viral encephalitis/meningitis in adult patients diagnosed with viral encephalitis/meningitis.


Subject(s)
Encephalitis, Viral , Encephalitis , Meningitis , Adult , Humans , Meningitis/cerebrospinal fluid , Meningitis/diagnosis , Lactic Acid , Plasma , Cerebrospinal Fluid
2.
Sci Rep ; 5: 13931, 2015 Sep 10.
Article in English | MEDLINE | ID: mdl-26355080

ABSTRACT

Corticosteroids have been proved to be ineffective for Guillain-Barré syndrome, but the mechanism remains unknown. In a rabbit model of axonal Guillain-Barré syndrome, treatment with corticosteroids significantly reduced macrophage infiltration in the spinal ventral roots and the survival rate as well as clinical improvement. On 30(th) day after onset, there was significantly higher frequency of axonal degeneration in the corticosteroids-treated rabbits than saline-treated rabbits. Corticosteroids may reduce the scavengers that play a crucial role for nerve regeneration, thus delay the recovery of this disease.


Subject(s)
Adrenal Cortex Hormones/pharmacology , Guillain-Barre Syndrome/etiology , Adrenal Cortex Hormones/administration & dosage , Animals , Axons/drug effects , Axons/metabolism , Disease Models, Animal , Guillain-Barre Syndrome/diagnosis , Guillain-Barre Syndrome/drug therapy , Macrophages/drug effects , Macrophages/immunology , Macrophages/metabolism , Macrophages/pathology , Motor Neurons/drug effects , Motor Neurons/metabolism , Motor Neurons/pathology , Nerve Regeneration/drug effects , Rabbits
3.
J Neuroimmunol ; 283: 1-6, 2015 Jun 15.
Article in English | MEDLINE | ID: mdl-26004148

ABSTRACT

Guillain-Barré syndrome (GBS) is a post-infectious autoimmune disease. Dendritic cells (DCs) can recognize the pathogen and modulate the host immune response. Exploring the role of DCs in GBS will help our understanding of the disease development. In this study, we aimed to analyze plasmacytoid and conventional DCs in peripheral blood of patients with GBS at different stages of the disease: acute phase as well as early and late recovery phases. There was a significant increase of plasmacytoid DCs in the acute phase (p=0.03 vs healthy donors). There was a positive correlation between percentage of plasmacytoid DCs and the clinical severity of patients with GBS (r=0.61, p<0.001). Quantitative polymerase chain reaction and flow cytometry confirmed the aberrant plasmacytoid DCs in GBS. Thus, plasmacytoid DCs may participate in the development of GBS.


Subject(s)
Dendritic Cells/immunology , Guillain-Barre Syndrome/immunology , Acute Disease , Adolescent , Adult , Aged , Aged, 80 and over , Antigens, CD/biosynthesis , Antigens, CD/genetics , Autoantibodies/blood , Autoantibodies/immunology , Autoantigens/immunology , Convalescence , Female , Flow Cytometry , Gangliosides/immunology , Guillain-Barre Syndrome/blood , Guillain-Barre Syndrome/genetics , Guillain-Barre Syndrome/physiopathology , Guillain-Barre Syndrome/therapy , Humans , Immunoglobulin G/blood , Immunoglobulins, Intravenous/therapeutic use , Male , Middle Aged , Neural Conduction , Plasma Exchange , Severity of Illness Index , Toll-Like Receptor 7/biosynthesis , Toll-Like Receptor 7/genetics , Toll-Like Receptor 9/biosynthesis , Toll-Like Receptor 9/genetics , Up-Regulation , Young Adult
4.
Trials ; 16: 111, 2015 Mar 24.
Article in English | MEDLINE | ID: mdl-25873334

ABSTRACT

BACKGROUND: Parkinson's disease (PD) is a common degenerative neurological disorder that causes loss of independence and decreased quality of life. The prevalence of PD tends to increase with age. In China, the morbidity rate of PD among people aged more than 65 years old is 1.70%. As an important component of traditional Chinese Qigong exercises, Tai Chi is a popular and safe exercise, especially for older adults in China. And it may result in promising gains for PD patients. However, current evidence is insufficient to inform the use of Tai Chi in the management of PD. Therefore, the aim of this trial is to systematically evaluate the effect of Tai Chi on PD and determine whether Tai Chi is an eligible exercise program for Chinese PD patients. METHODS/DESIGN: A single-blind, parallel randomized controlled trial will be conducted. One hundred and forty-two patients with PD will be randomly assigned to a Tai Chi group (n = 71) or routine exercise group (n = 71). Subjects will participate in supervised study programs 3 times per week for 2 months and will be followed for an additional 6 months after formal training stops. The primary outcome measures include Berg Balance Scale, Timed Up and Go Test and Six-Minute Walk Test, which are known to be valid and reliable clinical instruments. The Unified Parkinson's Disease Rating Scale Motor Section and Parkinson's Disease Questionnaire-39 will be used as the secondary outcome measure. All outcomes will be measured at baseline, 2 and 8 months. The sample for this trial (N = 142) will provide relevant information to detect the improvement of balance, gait and quality of life in either of the 2 exercise groups. DISCUSSION: Findings from this study will provide insights into the effects of Tai Chi in people with PD. The information gained from this project has the potential to influence the clinical decisions of Chinese doctors, and will provide clear evidence as to whether Tai Chi should be advocated in people with PD. TRIAL REGISTRATION: The trial was registered at ( ChiCTR-TRC-14004549 ) on 22 April 2014.


Subject(s)
Parkinson Disease/therapy , Tai Ji , Biomechanical Phenomena , China , Clinical Protocols , Exercise Test , Exercise Tolerance , Gait , Humans , Motor Activity , Parkinson Disease/diagnosis , Parkinson Disease/physiopathology , Parkinson Disease/psychology , Postural Balance , Quality of Life , Recovery of Function , Research Design , Single-Blind Method , Surveys and Questionnaires , Time Factors , Treatment Outcome
5.
Inflammation ; 36(2): 337-45, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23065188

ABSTRACT

MicroRNA-155 (miR155) has been demonstrated as a central regulator of immune responses induced by inflammatory mediators. Previous studies suggest that miR155 may play adverse effects in various diseases. We hereby explored the roles of miR155 in the pathogenesis of Guillain-Barré syndrome (GBS). Peripheral blood mononuclear cells (PBMCs) were separated from GBS patients and healthy controls. Expression of miR155 in PBMCs was detected by quantitative PCR. An inhibitor of miR155 was transfected into the cultured PBMCs and the GBS-related cytokines were detected. Significantly, our study demonstrated that miR155 was downregulated in PBMCs from GBS patients and silencing of miR155 profoundly promoted the production of Th1-type cytokines in vitro. Our data effectively demonstrate a protective role of miR155 in GBS, which suggests that miR155 may be a promising target for the therapy of the disease.


Subject(s)
Guillain-Barre Syndrome/genetics , Inflammation Mediators/metabolism , Inflammation/genetics , Leukocytes, Mononuclear/metabolism , MicroRNAs/genetics , Adult , Female , Humans , Interferon-gamma/analysis , Interleukin-12/analysis , Interleukin-1beta/analysis , Interleukin-4/analysis , Leukocytes, Mononuclear/cytology , Male , RNA Interference , RNA, Small Interfering , Tumor Necrosis Factor-alpha/analysis
6.
Neurosci Bull ; 28(5): 469-74, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22961471

ABSTRACT

OBJECTIVE: To evaluate the frequency, distribution and clinical significance of the antibodies to the fetal and/or adult acetylcholine receptor (AChR) in patients with myasthenia gravis (MG). METHODS: AChR antibodies were detected by cell-based assay in the serum of ocular MG (OMG) (n = 90) and generalized MG (GMG) patients (n = 110). The fetal-type (2α: ß: γ: δ) and adult-type (2α: ß: ε: δ) AChR were used as antigens, and their relevance to disease presentation was assessed. RESULTS: The overall frequencies of anti-adult and anti-fetal AChR antibodies were similar in all 200 patients examined, with 14 having serum specific to the AChR-Γ subunit, and 22 to the AChR-ε subunit. The overall sensitivity when using the fetal and adult AChR antibodies was higher than that when using the fetal AChR antibody only (P = 0.015). Compared with OMG patients, the mean age at disease onset and the positive ratio of antibodies to both isoforms of the AChR were significantly higher in patients who subsequently progressed to GMG. Older patients and patients with both anti-fetal and anti-adult AChR antibodies had a greater risk for developing generalized disease [odds ratio (OR), 1.03; 95% confidence interval (CI), 1.01-1.06 and OR, 5.09; 95% CI, 2.23-11.62]. CONCLUSION: Using both fetal- and adult-type AChRs as the antigens may be more sensitive than using either subtype. Patients with serum specific to both isoforms are at a greater risk of progressing to GMG. Patients with disease onset at an advanced age appear to have a higher frequency of GMG conversion.


Subject(s)
Autoantibodies/blood , Fetus/metabolism , Myasthenia Gravis/diagnosis , Myasthenia Gravis/immunology , Receptors, Cholinergic/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Autoantibodies/biosynthesis , Biomarkers/blood , Fetus/immunology , HEK293 Cells , Humans , Middle Aged , Myasthenia Gravis/blood , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL